Oncogenic action of pituitary-tumor transforming gene (PBF) in head and neck cancer is associated with poorer overall survival

Background Phase angle could be an alternative to subjective global assessment for the assessment of nutrition status in patients with head-and-neck cancer.Methods We prospectively evaluated a cohort of 75 stage iiib and iv head-and-neck patients treated at the Otolaryngology Department, Head and Neck Surgery, Medical University of Lublin, Poland. Bioelectrical impedance analysis was performed in all patients using an analyzer that operated at 50 kHz. The phase angle was calculated as reactance divided by resistance (Xc/R) and expressed in degrees. The Kaplan–Meier method was used to calculate survival.Results Median overall survival in the cohort was 32.0 months. At the time of analysis, 47 deaths had been recorded in the cohort (62.7%). The risk of shortened overall survival was significantly higher in patients whose phase angle was less than 4.733 degrees than in the remaining patients (19.6 months vs. 45 months, p = 0.0489; chi-square: 3.88; hazard ratio: 1.8856; 95% confidence interval: 1.0031 to 3.5446).Conclusions Phase angle might be prognostic of survival in patients with advanced head-and-neck cancer. Further investigation in a larger population is required to confirm our results.

Download Full-text

Investigation of relationship between change in locoregional control and change in overall survival in randomized controlled trials of modified radiotherapy in head-and-neck cancer

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2004.05.049 ◽

2004 ◽

Vol 60 (5) ◽

pp. 1405-1409 ◽

Cited By ~ 27

Author(s):

Jonathan C. Wadsley ◽

Søren M. Bentzen

Keyword(s):

Overall Survival ◽

Head And Neck Cancer ◽

Randomized Controlled Trials ◽

Head And Neck ◽

Neck Cancer ◽

Locoregional Control ◽

Controlled Trials ◽

Randomized Controlled

Download Full-text

140 Prognostic factors of overall survival for patients with recurrent head and neck cancer: a retrospective study

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(03)90173-x ◽

2003 ◽

Vol 1 (5) ◽

pp. S46

Author(s):

L. Chaigneau ◽

T. Nguyen ◽

U. Stein ◽

E. Guardiola ◽

A. Danzon ◽

...

Keyword(s):

Overall Survival ◽

Head And Neck Cancer ◽

Prognostic Factors ◽

Retrospective Study ◽

Head And Neck ◽

Neck Cancer ◽

Recurrent Head

Download Full-text

Tumor cells with low proteasome subunit expression predict overall survival in head and neck cancer patients

BMC Cancer ◽

10.1186/1471-2407-14-152 ◽

2014 ◽

Vol 14 (1) ◽

Cited By ~ 40

Author(s):

Chann Lagadec ◽

Erina Vlashi ◽

Sunita Bhuta ◽

Chi Lai ◽

Paul Mischel ◽

...

Keyword(s):

Overall Survival ◽

Head And Neck Cancer ◽

Head And Neck ◽

Cancer Patients ◽

Tumor Cells ◽

Neck Cancer ◽

Proteasome Subunit ◽

Subunit Expression

Download Full-text

Compliance and Outcomes in Locally Advanced Head and Neck Cancer Patients Treated with Alternating Chemoradiotherapy in Clinical Practice

Tumori Journal ◽

10.1177/030089160308900105 ◽

2003 ◽

Vol 89 (1) ◽

pp. 20-25 ◽

Cited By ~ 4

Author(s):

Vittorio Franciosi ◽

Marco Fumagalli ◽

Luciana Biscari ◽

Roberto Martinelli ◽

Teore Ferri ◽

...

Keyword(s):

Overall Survival ◽

Head And Neck Cancer ◽

Clinical Practice ◽

Head And Neck ◽

Cancer Patients ◽

Neck Cancer ◽

Locally Advanced ◽

Hematologic Toxicity ◽

Advanced Head ◽

Grade 3

Background and Aims To evaluate the feasibility in clinical practice of alternating chemo-radiotherapy in locally advanced head and neck cancer patients. Patients and Methods From August 1993 to April 1998 at the Division of Medical Oncology of Parma, 48 consecutive patients were observed, and 38 (79%) started the Merlano chemo-radiotherapy. The characteristics of the patients were: males (32, 84%); median age, 57 years; PS <2 (32, 84%). The primary sites were the oropharynx (18, 47%), oral cavity (8, 21%), hypopharynx (7, 19%), larynx (5, 13%); stage IV disease was present in 29 (76%) patients. Twenty-five (66%) patients were married, and 24 (63%) resided outside of the city. Results The compliance was very low: 21 patients (55%) performed all the programmed cycles of chemotherapy, whereas only 5 patients (13%) performed the chemo-radiotherapy at full doses without any delay. The objective responses were 3 (8%) complete and 21 (55%) complete plus partial responses. Failures were 2 (5%) stable disease and 2 (5%) progressive disease, and the response was not assessable in 10 (26%). The median duration of the response was 8 months. The median overall survival and the time to progression were 18 and 13 months, respectively; the 5-year overall and relapse-free survival were 36% and 26%, respectively. Nine (24%) patients were still alive as of August 30, 2001, 8 (21%) of them without progression. Twenty-six patients (68%) died with a local-regional relapse. One patient (3%) died for a second cancer. Grade 3–4 hematologic toxicity was leukopenia (n = 25, 66%) and thrombocytopenia (n = 9, 24%); grade 3–4 non-hematologic toxicity was diarrhea (n = 3, 8%) and mucositis (n = 2, 5%). Two patients (5%) died for intestinal infarction and perforation possibly related to treatment. Conclusions Compliance to the chemo-radiotherapy was very poor. The response rate was lower than that reported in clinical trials, whereas overall survival was comparable. The alternating chemo-radiotherapy is a very complex treatment that cannot be easily applied in clinical practice; a careful selection of patients is mandatory not only considering oncologic and medical criteria, but also the level of awareness of the patient and his family.

Download Full-text

Changing functional status within 6 months posttreatment is prognostic of overall survival in patients with head and neck cancer: NRG Oncology Study

Head & Neck ◽

10.1002/hed.25922 ◽

2019 ◽

Vol 41 (11) ◽

pp. 3924-3932 ◽

Cited By ~ 1

Author(s):

Ronald C. Eldridge ◽

Stephanie L. Pugh ◽

Andy Trotti ◽

Kenneth Hu ◽

Sharon Spencer ◽

...

Keyword(s):

Overall Survival ◽

Head And Neck Cancer ◽

Functional Status ◽

Head And Neck ◽

Neck Cancer

Download Full-text

Circulating MicroRNAs as Prognostic Molecular Biomarkers in Human Head and Neck Cancer: A Systematic Review and Meta-Analysis

Disease Markers ◽

10.1155/2019/8632018 ◽

2019 ◽

Vol 2019 ◽

pp. 1-12 ◽

Cited By ~ 3

Author(s):

Shree Ram Lamichhane ◽

Thanuja Thachil ◽

Harriet Gee ◽

Natalie Milic

Keyword(s):

Systematic Review ◽

Overall Survival ◽

Head And Neck Cancer ◽

Head And Neck ◽

Cancer Patients ◽

Neck Cancer ◽

Meta Analysis ◽

Prognostic Role ◽

Circulating Micrornas

Background. Circulating microRNAs (miRNAs) are potential molecular biomarkers for cancer detection; however, little is known about their prognostic role in head and neck cancer. This current study is aimed at evaluating the role of novel miRNAs in the survival of head and neck cancer patients. Materials and Methods. We performed a systematic literature search using online databases for articles published between December 2006 and February 2019. A meta-analysis was conducted to assess the correlation between miRNA expressions and overall survival (OS) among the selected head and neck cancer studies. After multilevel screening by reviewers, meta-analysis was performed using hazard ratios (HR) and associated 95% confidence interval (CI) of survival to calculate a pooled effect size. Result. A total of 1577 patients across 13 studies were included in the literature review, with 18 miRNAs upregulated and 4 miRNAs downregulated predicting a poor overall survival. The forest plot generated using cumulated survival data resulted in a pooled HR value of 2.943 (95% CI: 2.394-3.618) indicating a strong association of dysregulated miRNA expression with a poor outcome. Only 2 miRNAs—low levels of miR-9 and high levels of miR-483-5p—were observed in two studies, both showing a significant association with overall cancer survival. Conclusion. To our knowledge, this is the first comprehensive systematic review and meta-analysis that examines the prognostic role of circulating miRNAs from blood in head and neck cancer patients. The combined effect estimates a HR across multiple studies and also supports the previous individual findings that an alteration in miRNA expression is highly associated with poor prognosis. This has the potential to use serum and/or plasma miRNAs as biomarkers and become novel tools for predicting the prognosis of head and neck cancer patients in the near future.

Download Full-text